Literature DB >> 10687269

[Mefloquine and ototoxicity: a report of 3 cases].

M Fusetti1, A Eibenstein, V Corridore, S Hueck, S Chiti-Batelli.   

Abstract

We report these cases of high-frequency sensorineural hearing loss and tinnitus, following malaria prophylaxis with mefloquine (Lariam). Only one patient had partial remission of hearing loss after suspension of the treatment. In the remaining two cases the symptomatology remained unchanged. None of the patients reported improvement of tinnitus. Our experience suggests that a routine audiologic evaluation, before and after prophylactic use of antimalarial drugs, is important to monitor potential hearing deficit.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10687269

Source DB:  PubMed          Journal:  Clin Ter        ISSN： 0009-9074


  9 in total

1.  Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013.

Authors:  Keren Z Landman; Kathrine R Tan; Paul M Arguin
Journal:  Travel Med Infect Dis       Date:  2014-12-11       Impact factor: 6.211

2.  Mefloquine damage vestibular hair cells in organotypic cultures.

Authors:  Dongzhen Yu; Dalian Ding; Haiyan Jiang; Daniel Stolzberg; Richard Salvi
Journal:  Neurotox Res       Date:  2010-09-22       Impact factor: 3.911

Review 3.  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M J Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

4.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

Review 5.  Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed?

Authors:  Virginia Ramos-Martín; Carmen González-Martínez; Ian Mackenzie; Joachim Schmutzhard; Cheryl Pace; David G Lalloo; Dianne J Terlouw
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

6.  Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.

Authors:  Sue J Lee; Feiko O Ter Kuile; Ric N Price; Christine Luxemburger; François Nosten
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

7.  Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.

Authors:  Robert Gürkov; Teferi Eshetu; Isabel Barreto Miranda; Nicole Berens-Riha; Yoseph Mamo; Tsinuel Girma; Eike Krause; Michael Schmidt; John-Martin Hempel; Thomas Löscher
Journal:  Malar J       Date:  2008-09-16       Impact factor: 2.979

8.  Addition of exogenous NAD+ prevents mefloquine-induced neuroaxonal and hair cell degeneration through reduction of caspase-3-mediated apoptosis in cochlear organotypic cultures.

Authors:  Dalian Ding; Weidong Qi; Dongzhen Yu; Haiyan Jiang; Chul Han; Mi-Jung Kim; Kana Katsuno; Yun Hua Hsieh; Takuya Miyakawa; Richard Salvi; Masaru Tanokura; Shinichi Someya
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.752

Review 9.  Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.

Authors:  Stuart McCarthy
Journal:  J Parasitol Res       Date:  2015-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.